Study of HSK42360 for brain tumors with BRAF V600 mutation in children
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug, HSK42360, for children with recurrent brain tumors that have a specific gene change called BRAF V600. The goal is to see if the drug can help when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 17 years old.
- Your brain tumor has come back after standard treatment and has a specific gene change (BRAF V600 mutation).
- You are able to perform daily activities with minimal help (performance status score above 60).
- You have not had other cancer in the last 2 years (except for some low-risk types).
- Your heart, liver, kidneys, and blood counts are working well enough.
- You are not pregnant or breastfeeding, and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HSK42360, for people with advanced solid tumors that have a specific gene change called BRAF V600. It may be an option if other treatments have stopped working.
This is an early-stage study testing a new investigational drug (HSK42360-Na) designed to target a specific genetic mutation (BRAF V600) found in some advanced or metastatic cancers. The goal is to see if this drug is safe and effective for patients whose cancers have grown despite prior treatments.
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
This trial tests a new targeted medicine (FCN-159) against standard chemotherapy for children with slow-growing brain or nervous system tumors that have a specific genetic change (BRAF alteration). The goal is to see if the new pill works better at shrinking or controlling the tumor.
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
Hear when a new Malignant Brain Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.